US-based interventional technologies provider NICO has secured a CE mark for its patented technology 'BrainPath' to provide non-disruptive access to the brain.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to be compatible with a parafascicular and trans-sulcal surgical approach, the technology will now be available in more than 30 countries in the European Union (EU).

A part of new standardised brain surgery approach, BrainPath runs parallel to the fibre tracts as a path to the surgical site, utilising the natural folds of the brain.

The approach achieves non-disruptive access and automated tissue removal / clot evacuation, as well as intraoperative tumour tissue collection and preservation through a combination of patented technologies.

See Also:

BrainPath unites imaging and intervention to provide guided atraumatic access within the brain via trans-sulcal, parafascicular surgical approach.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It gently moves the brain tissue to generate a corridor to the tumour or hemorrhage site.

"Gaining CE mark approval for BrainPath is our first step in answering increasing global interest in a systems approach to subcortical brain surgery using a standardised approach."

NICO president and chief executive officer Jim Pearson said: “Gaining CE mark approval for BrainPath is our first step in answering increasing global interest in a systems approach to subcortical brain surgery using a standardised approach.

“We intend to take a planned approach to global expansion and look forward to making a positive difference in the worldwide brain tumour and stroke incidence rate.”

Intended for subcortical access, BrainPath can be used for specific indications such as primary and secondary brain tumours, vascular abnormalities resulting in intracerebral hemorrhage (ICH) or hemorrhagic stroke and secondary bleeds, and intraventricular tumours or cysts.

Based on the available clinical data, BrainPath is reported to show overall safety, performance and can be used anywhere in the white matter of the brain.

Image: NICO BrainPath patented technology. Photo: courtesy of Business Wire.